Trending With Impact: Real-World Treatment Patterns of Alectinib in Unselected Spanish ALK+ NSCLC Patients

4 views

|

June 16, 2022

Oncotarget published this trending research paper on June 15, 2022 in Volume 13, entitled, "Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program" by researchers from Department of Medical Oncology, Hospital Virgen del Rocío, Sevilla, Spain; Department of Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Department of Medical Oncology, Hospital Universitario A Coruña, A Coruña, Spain; Department of Medical Oncology, ICO Bellvitge, Hospitalet Llobregat, Barcelona, Spain; Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain; Department of Medical Oncology, Hospital General Yague, Burgos, Spain; Department of Medical Oncology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Department of Medical Oncology, Hospital Marqués de Valdecilla, Santander, Spain; Department of Medical Oncology, Hospital Universitario Donostia, Donostia-San Sebastián, Spain; Department of Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain; Department of Medical Oncology, Hospital Universitario La Princesa, Madrid, Spain; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Medical Oncology, Complejo Asistencial Universitario de León, León, Spain; Roche Farma, S.A., Madrid, Spain; Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain. DOI - https://doi.org/10.18632/oncotarget.28244 Correspondence to - Reyes Bernabé-Caro - reyesbernab@yahoo.es Abstract This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive non-small-cell lung cancer (ALK+ NSCLC) according to data collected between November 2019 and October 2020 in 38 Spanish hospitals. Patients had progressed after 1–5 prior treatment lines (which included crizotinib in any prior line) and received subsequent therapy with alectinib in a local expanded access program. Median age was 58.7 years, 50% of patients were female, 64.1% had ECOG PS of 0–1, 85% presented stage IV, 95% had adenocarcinoma histology and 20.8% had brain metastases. After a median 9.6 months of alectinib treatment, objective response rate (ORR) was 54.5%, disease control rate (DCR) was 80%, median progression-free survival (PFS) was 9.4 months and median overall survival (OS) was 24.1 months. Patients with brain metastases achieved an intracranial DCR of 71.4%. Adverse events (AEs) were reported in 35.8% of patients (14.2% of AEs were grade ≥3). Over 40% of patients received some treatment after alectinib, most frequently lorlatinib (65.2%) and brigatinib (32.6%). This study provides information on real-world treatment patterns and confirms the tolerability and prolonged PFS and OS observed with alectinib in clinical trials, in unselected pretreated patients with advanced ALK+ NSCLC. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28244 Keywords - lung cancer, ALK-positive NSCLC, ALK inhibitor, crizotinib, alectinib, unselected patient About Oncotarget Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

BiopharmaCancer ResearchChemistryImmunology

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.